JACCRO CC-11 study

Interventions: FOLFOXIRI+/-bevacizumab (To 12 courses), 5-FU+Levofolinate+/-bevacizumab (From 13 courses) given on day 1 every 2 weeks, until disease progression or unmanageable toxicity. bevacizumab 5mg/kg/bi-weekly Irinotecan 150mg/m2/bi-weekly Oxaliplatin 85mg/m2/bi-weekly Levofolinate 200mg/m2/bi-weekly 5-FU 2400mg/m2/bi-weekly Primary outcome(s): Response Rate Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose